

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On JUNE 3, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: MARK T. DAVIS

Attorney Docket No.: 20553C-003310US
Client Reference No.: ECV-8628

1648
PATENT
RECEIVED

JUN 09 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Crystal M. Cunanan, et al.

Application No.: 09/930,619

Filed: August 15, 2001

For: TREATMENT OF TISSUE,
INSTRUMENTS AND WORK
SURFACES TO REMOVE INFECTIOUS
AGENTS

Examiner: Winkler, Ulrike

Art Unit: 1648

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kenneth E. Jenkins
Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
MTD:mtd
SF 1463669 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

1

of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-4,729,139	03-08-1988	Nashef	
	AB	US-5,622,861	04-22-1997	Kaplan et al.	
	AC	US-5,633,349	05-27-1997	Reichl	
	AD	US-5,756,678	05-26-1998	Shenoy et al.	
	AE	US-5,780,288	07-14-1998	Rohwer	
	AF	US-5,808,011	09-15-1998	Gawryl et al.	
	AG	US-5,997,895	12-07-1999	Narotam et al.	
	AH	US-6,008,292	12-28-1999	Lee et al.	
	AI	US-6,150,172	11-21-2000	Schmerr et al.	
	AJ	US-6,197,935 B1	03-06-2001	Doillon et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AK	✓ WO	96/05846	A1	02-29-1996			<input type="checkbox"/>
	AL	✓ WO	97/45746	A2	12-04-1997			<input type="checkbox"/>
	AM	✓ WO	00/43782	A2	07-27-2000			<input type="checkbox"/>
	AN	✓ WO	00/78344	A1	12-28-2000			<input type="checkbox"/>
	AO	✓ WO	01/00235	A1	01-04-2001			<input type="checkbox"/>
	AP	✓ WO	02/043778	A3	06-06-2002			<input type="checkbox"/>

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of **Complete if Known**

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

RECEIVED
JUN 0 9 2003
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AQ	Adjou, <i>et al.</i> , "MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters," <i>J Comp Pathol</i> , 122(1):3-8 (2000).	
	AR	Akula, <i>et al.</i> , "Human herpesvirus 8 interaction with target cells involves heparin sulfate," <i>Virology</i> , 282(2):245-55 (2001).	
	AS	Alkhalil, A., <i>et al.</i> , "Structural requirements for the adherence of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate proteoglycans of human placenta," <i>J Biol Chem</i> , 275(51):40357-64 (2000).	
	AT	Arnold, JE, <i>et al.</i> , "The abnormal isoform of the prion protein accumulates in late-endosome-like organelles in scrapie-infected mouse brain," <i>J Pathol</i> , 176(4) 403-11 (1995).	
	AU	Balbirnie, <i>et al.</i> , "An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated β -sheet structure for amyloid," <i>PNAS</i> , 98(5):2375-2380 (2001).	
	AV	Baranowski, <i>et al.</i> , "Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: Flexibility in aphthovirus receptor usage," <i>J Virology</i> , 74(4):1641-1647 (2000).	
	AW	Barillari, <i>et al.</i> , "The tat protein of human immunodeficiency virus Type-1 promotes vascular cell growth and locomotion by engaging the $\alpha 5\beta 1$ and $\alpha v\beta 3$ integrins and by mobilizing sequestered basic fibroblast growth factor," <i>Blood</i> , 94(2):663-672 (1999).	
	AX	Batinic, <i>et al.</i> , "The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides," <i>J Biol Chem</i> , 267(10):6664-71 (1992).	
	AY	Beringue, <i>et al.</i> , "Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice," <i>J Gen Virol</i> , 80(Pt 7):1873-7 (1999).	
	AZ	Beringue, <i>et al.</i> , "Pharmacological manipulation of early PrPres accumulation in the spleen of scrapie-infected mice," <i>Arch Virol Suppl</i> , (16):39-56 (2000).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 3 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

RECEIVED
JUN 08 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	Beringue, et al., "Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent," <i>J Virology</i> , 74(12):5432-5440 (2000).	
	BB	Blase, et al., "Lipoteichoic acid inhibits lipopolysaccharide-induced adhesion molecule expression and IL-8 release in human lung microvascular endothelial cells," <i>J Immunology</i> , 163:6139-6147 (1999).	
	BC	Borchelt, et al., "Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor," <i>Glycobiology (ENGLAND)</i> , 3(4):319-29 (1993).	
	BD	Brimacombe, et al., "Characterization and polyanion-binding properties of purified recombinant prion protein," <i>Biochem J</i> , 342(Pt 3):605-613 (1999).	
	BE	Brown et al., "Newer Data on the Inactivation of Scrapie Virus or Creutzfeldt-Jakob Disease Virus in Brain Tissue", <i>J. Infect. Dis.</i> 153(6): 1145-1148 (1986).	
	BF	Bruett, L., et al., "Characterization of a membrane-associated protein implicated in visna virus binding and infection," <i>Virology</i> , 271(1):132-41 (2000).	
	BG	Byrnes et al., "Binding of Sindbis Virus to Cell Surface Heparan Sulfate," <i>J. Virol.</i> 72(9):7349-7356 (1998).	
	BH	Callahan, et al., "Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions," <i>J Virol</i> , 65(3):1543-50 (1991).	
	BI	Caughey, et al., "Scrapie-associated PrP accumulation and agent replication: effects of sulphated glycosaminoglycan analogues", <i>Phil. Trans. R. Soc. Lond. B</i> 343:399-404 (1994).	
	BJ	Caughey, et al., "Scrapie-associated PrP accumulation and its inhibition: revisiting the amyloid-glycosaminoglycan connection," <i>Ann N Y Acad Sci</i> , 724:290-5 (1994).	
	BK	Caughey, et al., "Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines," <i>Proc. Natl. Acad. Sci. USA</i> , 95:12117-12122 (1998).	

Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

4

of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER 1600/2900
JUN 09 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	✓ Caughey <i>et al.</i> , "Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red," <i>J. Virol.</i> 68(4): 2135-2141 (1994).	
	BM	✓ Caughey, <i>et al.</i> , "Scrapie-associated PrP accumulation and agent replication: effects of sulphated glycosaminoglycan analogues, <i>Phil. Trans. R. Soc. Lond. B</i> 343:399-404 (1994).	
	BN	✓ Cox, Institute for International Research Conference, March 15-16, 1999, San Diego.	
	BO	✓ Cross, "Eukaryotic Protein Modification and Membrane Attachment Via Phosphatidylinositol," <i>Cell</i> 48: 179-181 (1987).	
	BP	✓ Darbord, JC, "Inactivation of prions in daily medicine practice," <i>Biomed Pharmacother.</i> 53(1):34-8 (1999).	
	BQ	✓ De Kimpe, <i>et al.</i> , "The cell wall components peptidoglycan and lipoteichoic acid from <i>Staphylococcus aureus</i> act in synergy to cause shock and multiple organ failure," <i>Proc. Natl. Acad. Sci. USA</i> , 92:10359-10363 (1995).	
	BR	✓ Demaimay <i>et al.</i> , "Inhibition of Formation of Protease-Resistant Prion Protein by Trypan Blue, Sirius Red and Other Congo Red Analogs," <i>Arch. Virol. Suppl.</i> 16: 277-283 (2000).	
	BS	✓ Di Martino <i>et al.</i> , "The Consistent Use of Organic Solvents for Purification of Phospholipids from Brain Tissue Effectively Removes Scrapie Activity," <i>Biologicals</i> 22(3):221-225 (1994).	
	BT	✓ Doh-ura, <i>et al.</i> , "Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation," <i>J Virology</i> , 74(10):4894-4897 (2000).	
	BU	✓ Dziarski, R., <i>et al.</i> , "Heparin, sulfated heparinoids, and lipoteichoic acids bind to the 70-kDa peptidoglycan/lipopolysaccharide receptor protein on lymphocytes," <i>J Biol Chem</i> , 269(3):2100-10 (1994).	
	BV	✓ Ehlers <i>et al.</i> , "Dextran Sulphate 500 Delays and Presents Mouse Scrapie by Impairment of Agent Replication in Spleen," <i>J. Gen. Virol.</i> 65: 1325-1330 (1984).	
	BW	✓ Feigelstock, <i>et al.</i> , "The human homolog of HAVcr-1 codes for a Hepatitis A virus cellular receptor," <i>J Virol</i> , 72(8):6621-6628 (1998).	

Examiner
Signature


Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 5 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

RECEIVED
JUN 09 2003
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BX	Feigelstock <i>et al.</i> , "Polymorphisms of the Hepatitis A Virus Cellular Receptor 1 in African Green Monkey Kidney Cells Result in Antigenic Variants That Do No React with Protective Monoclonal Antibody 190/4," <i>J. Virol.</i> , 72 (7):6218-6222 (1998).	
	BY	Foster <i>et al.</i> , "Phosphatidylethanolamine Recognition Promotes Enteropathogenic <i>E. coli</i> and Enterohemorrhagic <i>E. coli</i> Host Cell Attachment," <i>Microb. Pathog.</i> 27 (5): 289-301 (1999).	
	BZ	Fundacao Antonio Prudente, "A receptor for infectious and cellular prion protein," <i>Braz J Med Biol Res</i> , 32 (7):853-9 (1999).	
	CA	Futerman <i>et al.</i> , "Identification of Covalently Bound Inositol in the Hydrophobic Membrane-Anchoring Domain of Torpedo acetylcholinesterase," <i>Biochem. Biophys. Res. Commun.</i> 129 (1): 312-317 (1985).	
	CB	Gabizon, R., <i>et al.</i> , "Purified prion proteins and scapie infectivity copartition into liposomes," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 84 (12):4017-21 (1987).	
	CC	Gasset, M., <i>et al.</i> , "Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity," <i>Proc. Natl. Acad. Sci. USA</i> , 90 :1-5 (1993).	
	CD	Giroglou <i>et al.</i> , "Human Papillomavirus Infection Requires Cell Surface Heparan Sulfate," <i>J. Virol.</i> 75 (3):1565-1570 (2001).	
	CE	Gonzalez <i>et al.</i> , "Polysaccharides as Antiviral Agents: Antiviral Activity of Carrageenans," <i>Antimicrob. Agents Chemother.</i> 31 (9):1388-1393 (1987).	
	CF	Goodfellow <i>et al.</i> , "Echoviruses Bind Heparan Sulfate at the Cell Surface," <i>J. Virol.</i> 75 (10):4918-4921 (2001).	
	CG	Gorodinsky, A, <i>et al.</i> , "Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin," <i>J Cell Biol</i> , 129 (3):619-27 (1995).	
	CH	Gotoh <i>et al.</i> , "Sulfated Fibroin, a Novel Sulfated Peptide Derived from Silk, Inhibits Human Immunodeficiency Virus Replication in Vitro," <i>Biosci. Biotechnol. Biochem.</i> 64 (8):1664-1670 (2000).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 6 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER 1600-2990
JUN 9 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CI	Grant et al., "Proteoglycan Receptor Binding by <i>Neisseria Gonorrhoeae</i> MS11 is Determined by the HV-1 Region of OpaA," <i>Mol. Microbiol.</i> 32(2): 233-242 (1999).	
	CJ	Hallak, et al., "Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection," <i>Virology</i> , 271(2):264-75 (2000).	
	CK	Hermann, LM, "Cellular prion protein is expressed on peripheral blood mononuclear cells but not platelets of normal and scrapie-infected sheep," <i>Haematologica</i> , 86(2):146-53 (2001).	
	CL	Herold et al., "Sulfated Carbohydrate Compounds Prevent Microbial Adherence by Sexually Transmitted Disease Pathogens," <i>Antimicrob. Agents Chemother.</i> 41(12):2776-2780 (1997).	
	CM	Hilgard et al., "Heparan Sulfate Proteoglycans Initiate Dengue Virus Infection of Hepatocytes," <i>Hepatology</i> 32(5): 1069-1077 (2000).	
	CN	Hirakura, et al., "Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block)," <i>Amyloid</i> , 7(3):194-9 (2000).	
	CO	Hooper, N.M., "Glycosyl-phosphatidylinositol anchored membrane enzymes," <i>Clin Chim Acta</i> , 266(1):3-12 (1997).	
	CP	Horiuchi, et al., "Interactions between heterologous forms of prion protein: Binding, inhibition of conversion, and species barriers," <i>PNAS</i> , 97(11):5836-5841 (2000).	
	CQ	Hsiao et al., "Vaccinia Virus Envelope D8L Protein Binds to Cell Surface Chondroitin Sulfate and Mediates the Adsorption of Intracellular Mature Virions to Cells," <i>J. Virol.</i> 73(10):8750-8761 (1999).	
	CR	Hulst, et al., "Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparin sulfate due to a single amino acid change in envelope protein E ^{rns} ," <i>J Virology</i> , 74(20):9553-9561 (2000).	
	CS	Inn et al., "Cellular Invasion of <i>Orientia Tsutsugamushi</i> Requires Initial Interaction with Cell Surface Heparan Sulfate," <i>Microb. Pathog.</i> 28(4):227-233 (2000).	
	CT	Iqbal, et al., "Interactions of bovine viral diarrhea virus glycoprotein E(rns) with cell surface glycosaminoglycans," <i>J Gen Virol</i> , 81(Pt 2):451-9 (2000).	

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 7 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER 1600/2900
JUN 09 2003
RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	Jackson, et al., "Efficient infection of cells in culture by Type O foot-and-mouth disease virus requires binding to cell surface heparin sulfate," <i>J Virology</i> , 70(8):5282-5287 (1996).	
	CV	Kaneko, et al., "COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform," <i>Proc Natl Acad Sci USA</i> , 94:2333-2338 (1997).	
	CW	Kaplan, G., "Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus," <i>EMBO J</i> , 15(16):4282-96 (1996).	
	CX	Kawahara, M., Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line," <i>J. Biological Chemistry</i> , 275(19):14077-83 (2000).	
	CY	Kengatharan, et al., "Mechanism of gram-positive shock: Identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure," <i>J. Exp. Med.</i>	
	CZ	Keshet, GI, et al., "The cellular prion protein colocalizes with the dystroglycan complex in the brain," <i>J Neurochem</i> , 75(5):1889-97 (2000).	
	DA	Kimberlin et al., "Disinfection Studies with Two Strains of Mouse-Passaged Scrapie Agent", <i>J. Neurol. Sci.</i> 59: 355-369 (1983).	
	DB	Kooyman, DL, et al., "Glycosyl phosphatidylinositol anchor," <i>Exp Nephrol</i> , 6(2):148-51 (1998).	
	DC	Lehmann, Sylvain, et al., "A mutant prion protein displays an aberrant membrane associate when expressed in cultured cells," <i>J Biol Chem</i> , 270(41):24589-24597 (1995).	
	DD	Li et al., "Integrin Alpha(v)beta(1) is an Adenovirus Coreceptor," <i>J. Virol.</i> 75(11):5405-5409 (2001).	
	DE	Liu, et al., "Heparin/heparin sulfate (HP/HS) interacting protein (HIP) supports cell attachment and selective, high affinity binding of HP/HS," <i>J Biol Chem</i> , 272(41):25856-25862 (1997).	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 8

of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH. CENTER 1600/2900
JUN 09 2003
RECEIVED**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DF	Liu, <i>et al.</i> , "A peptide sequence of heparin/heparin sulfate (HP/HS)-interacting protein supports selective, high affinity binding of HP/HS and cell attachment," <i>J Biol Chem</i> , 273(16):9718-9726 (1998).	
	DG	Liu, <i>et al.</i> , "A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1739-1744 (1997).	
	DH	Low <i>et al.</i> , "Phosphatidylinositol is the Membrane-Anchoring Domain of the Thy-1 Glycoprotein," <i>Nature</i> 318(6041): 62-64 (1985).	
	DI	Low <i>et al.</i> , "Role of Phosphatidylinositol in Attachment of Alkaline Phosphatase to Membranes," <i>Biochem.</i> 19(17): 3913-3918 (1980).	
	DJ	Lynch, <i>et al.</i> , "Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection," <i>J Leukoc Biol</i> , 56(3):266-72 (1994).	
	DK	MacGregor, <i>et al.</i> , "Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - comparison with effects upon anticoagulant activity, lipolysis and platelet α -granule proteins," <i>Thromb Haemostasis</i> , 53(3):411-414 (1985).	
	DL	Mangé <i>et al.</i> , "Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures," <i>J. Virol.</i> 74(7): 3135-3140 (2000).	
	DM	Martin, CH, <i>et al.</i> , "Allografts in otology. Potential risk of prion contamination. Current status of knowledge and legislation.," <i>Ann Otolaryngol Chir Chervicofac</i> , 112(5):241-3 (1995).	
	DN	McBride, <i>et al.</i> , "Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice," <i>Exp Neurol</i> , 149(2):447-54 (1998).	
	DO	McKinley MP, <i>et al.</i> , "Molecular characteristics of prion rods purified from scrapie-infected hamster brains," <i>J Infect Dis</i> , 154(10):110-20 (1986).	
	DP	Milhavet, O., <i>et al.</i> , "Effect of Congo red on wild-type and mutated prion proteins in cells," <i>J Neurochem</i> , 74(1):222-30 (2000).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 9 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER JUN 09 2003 RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DQ	✓ Miller <i>et al.</i> , "Role of the Cytoplasmic Domain of the Beta-Subunit of Integrin Alpha(v)beta(6) in Infection by Foot and Mouth Disease Virus," <i>J. Virol.</i> 75(9):4158-4164 (2001).	
	DR	✓ Millson <i>et al.</i> , in Prusiner and Hadlow, eds. SLOW TRANSMISSIBLE DISEASES OF THE NERVOUS SYSTEM, vol. II. New York: Academic Press 409-424 (1979).	
	DS	✓ Molinari <i>et al.</i> , "Two Distinct Pathways for the Invasion of <i>Streptococcus pyogenes</i> in Non-Phagocytic Cells," <i>Cell Microbiol.</i> 2(2): 145-154	
	DT	✓ Morelon, E., "The failure of Daudi cells to express the cellular prion protein is caused by a lack of glycosyl-phosphatidylinositol anchor formation," <i>Immunology</i> , 102(2):242-247 (2001).	
	DU	✓ Morillas, M., <i>et al.</i> , "Membrane environment alters the conformational structure of the recombinant human prion protein," <i>J Biol Chem</i> , 274(52):36859-36865 (1999).	
	DV	✓ Mouillet-Richard S., <i>et al.</i> , "Signal transduction through prion protein," <i>Science</i> , 289(5486):1925-8 (2000).	
	DW	✓ Multhaup, <i>et al.</i> , "The protein component of scrapie-associated fibrils is a glycosylated low molecular weight protein," <i>EMBO J</i> , 4(6):1495-1501 (1985).	
	DX	✓ Narwa, R., <i>et al.</i> , "Prior proteins carrying pathogenic mutations are resistant to phospholipase cleavage of their glycolipid anchors," <i>Biochemistry</i> , 6:38(27):8770-7 (1999).	
	DY	✓ Naslavsky, N., <i>et al.</i> , "Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform," <i>J Biol Chem</i> , 272(10):6324-31 (1997).	
	DZ	✓ Naslavsky, N., <i>et al.</i> , "Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions," <i>J Biol Chem</i> , 274(30):20763-71 (1999).	
	EA	✓ Neyts, <i>et al.</i> , "Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparin sulfate," <i>Virology</i> , 189(1):48-58 (1992).	
	EB	✓ Ortega-Barria, <i>et al.</i> , "A <i>toxoplasma</i> lectin-like activity specific for sulfated polysaccharides is involved in host cell infection," <i>J Biol Chem</i> , 274(3):1267-1276 (1999).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 10 of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER 1600/2900 JUN 9 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EC	Pancake, et al., "Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates," <i>J Cell Biol</i> , 117(6):1351-7 (1992).	
	ED	Panjwani et al., "Pathogenesis of Corneal Infection: Binding of <i>Pseudomonas aeruginosa</i> to Specific Phospholipids," <i>Infect. Immun.</i> 64(5): 1819-1825 (1996).	
	EE	Papakonstantinou, et al., "Glycosaminoglycan analysis in brain stems from animals infected with the bovine spongiform encephalopathy agent," <i>Arch Biochem Biophys</i> , 370(2):250-7 (1999).	
	EF	Parish, et al., "A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region," <i>J Immunol</i> , 145(4):1188-95 (1990).	
	EG	Perez, et al., "Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment," <i>Biochem J</i> , 335(Pt 2):369-74 (1998).	
	EH	Piret, et al., "In Vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against Herpes Simplex and human immunodeficiency viruses," <i>J Clin Microbiol</i> , 38(1):110-119 (2000).	
	EI	Pocchiari et al., "Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human Growth Hormone ?", <i>Arch. Virol.</i> 98: 131-135 (1988).	
	EJ	Priola, et al., "Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis," <i>Mol Neurobiol</i> , 8(2-3):113-20 (1994).	
	EK	Priola, et al., "Prion protein and the scrapie agent: in vitro studies in infected neuroblastoma cells," <i>Infect Agents Dis</i> , 3(2-3):54-8 (1994).	
	EL	Priola et al., "Porphyrin and Phthalocyanine Antiscrapie Compounds," <i>Science</i> 287: 1503-1506 (2000).	
	EM	Prusiner, SB, et al., "Scrapie prions aggregate to form amyloid-like birefringent rods," <i>Cell</i> , 35(2 Pt 1):349-58 (1983).	
	EN	Prusiner, SB, et al., "Attempts to restore scrapie prion infectivity after exposure to protein denaturants," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2793-2797 (1993).	
	EO	Prusiner et al., "Thiocyanate and hydroxyl ions inactivate the scrapie agent", <i>Proc. Natl. Acad. Sci. USA</i> 78(7): 4606-4610 (1981).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

11

of

Complete if Known

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et. al
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER 1600/2900 JUN 9 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EP	Race, "The Trouble with Transmissible Degenerative Encephalopathy Agents", <i>The Veterinary Journal</i> , 159: 3-4 (2000).	
	EQ	Ragni, et al., "Plasma fibronectin levels in clinical disease states and after cryoprecipitate infusion," <i>Thromb Haemostas</i> , 52(3):321-324 (1984).	
	ER	Rohde, et al., "Cell surface expression of HIP, a novel heparin/heparin sulfate-binding protein, of human uterine epithelial cells and cell lines," 271(20):11824-11830 (1996).	
	ES	Rogers, M., et al., "Conversion of truncated and elongated prior proteins into the scrapie isoform in cultured cells," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 90(8):3182-6 (1993).	
	ET	Rymer, et al., "The role of prion peptide structure and aggregation in toxicity and membrane binding," <i>J Neurochem</i> , 75(6):2536-2545 (2000).	
	EU	Safar, J., et al., "Differences in the membrane interaction of scrapie amyloid precursor proteins in normal and scrapie- or Creutzfeldt-Jakob disease-infected brains," <i>J. Infect Dis</i> , 163(3):488-94 (1991).	
	EV	Schussler, et al., "Effect of human immunoglobulins on the immunogenicity of porcine bioprostheses," <i>Ann Thorac Surg</i> , 7(5 Suppl):S396-400 (2001).	
	EW	Shyng, et al., "Sulfated glycans stimulate endocytosis of the cellular isoform of the prior protein, PrP ^C , in cultured cells," <i>J Biol Chem</i> , 270(50):30221-30229 (1995).	
	EX	Silberstein et al., "Neutralization of Hepatitis A Virus (HAV) by an Immunoadhesion Containing the Cysteine-Rich Region of HAV Cellular Receptor-1," <i>J. Virol</i> , 75(2):717-725 (2001).	
	EY	Snow, et al., "Immunolocalization of heparin sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie," <i>Lab Invest</i> , 63(5):601-11 (1990).	
	EZ	Stahl, N., et al., "Prions and prion proteins," <i>FASEB J</i> , 5(13):2799-807 (1991).	
	FA	Stinson, et al., "Streptococcal histone-like protein: primary structure of hlpA and protein binding to lipoteichoic acid and epithelial cells," <i>Infection and Immunity</i> , 66(1):259-265 (1998).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SF 1463669 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


RECEIVED
JUN 9 2003
TECH CENTER 1600/2200

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/930,619
		Filing Date	August 15, 2001
		First Named Inventor	Cunanan, Crystal M., et. al.
		Art Unit	1648
		Examiner Name	Winkler, Ulrike
		Attorney Docket Number	20553C-003310US
Page	12	of	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FB ✓	Su, et al., "Sulfated polysaccharides and a synthetic sulfated polymer are potent inhibitors of <i>Chlamydia trachomatis</i> infectivity <i>in vitro</i> but lack protective efficacy in an <i>in vivo</i> murine model of chlamydial genital tract infection," <i>Infection and Immunity</i> , 66(3):1258-1260 (1998).	
	FC ✓	Summerford, et al., "Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions," <i>J Virol</i> , 72(2):1438-45 (1998).	
	FD ✓	Supattapone, S., et al., "Branched polyamines cure prion-infected neuroblastoma cells," <i>J Virol</i> , 75(7):3453-61 (2001).	
	FE ✓	Supattapone, S., "Elimination of prions by branches polyamines and implication therapeutics," <i>Proc Natl Acad Sci USA</i> , 96(25):14529-34 (1999).	
	FF ✓	Sylvester et al., "Adherence to Lipids and Intestinal Mucin by a Recently Recognized Human Pathogen, <i>Campylobacter upsaliensis</i> ," <i>Infect. Immun.</i> 64(10): 4060-4066 (1996).	
	FG ✓	Tagliavini et al., "Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters," <i>Science</i> 276: 1119-1122 (1997).	
	FH ✓	Taraboulos, A., et al., "Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform," <i>J Cell Biol</i> , 129(1):121-32 (1995).	
	FI ✓	Taylor, DM, "Inactivation of prions by physical and chemical means," <i>J. Hosp Infect</i> , 43 Suppl:S69-76 (1999).	
	FJ ✓	Taylor, DM, "Inactivation of transmissible degenerative encephalopathy agents: A review.," <i>Vet J.</i> , 159(1):3-4 (2000).	
	FK ✓	Thompson et al., "The Cys-Rich Region of Hepatitis A Virus Cellular Receptor 1 is Required for Binding of Hepatitis A Virus and Protective Monoclonal Antibody 190/4," <i>J. Virol.</i> , 72(5): 3751-3761 (1998).	
	FL ✓	Utt et al., "Helicobacter Pylori Vacuolating Cytotoxin Binding to a Putative Cell Surface Receptor, Heparan Sulfate, Studied by Surface Plasmon Resonance," <i>FEMS Immunol. Med. Microbiol.</i> 30(2):109-113 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page **13** of**Complete if Known**

Application Number	09/930,619
Filing Date	August 15, 2001
First Named Inventor	Cunanan, Crystal M., et al.
Art Unit	1648
Examiner Name	Winkler, Ulrike
Attorney Docket Number	20553C-003310US

TECH CENTER JUN 09 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FM	Valenzuela-Fernandez <i>et al.</i> , "Optimal Inhibition of X4 Isolates by the CXCR4 Chemokine SDF-1a Requires Interaction with Cell-Surface Heparan Sulfate Proteoglycan," <i>J. Biol. Chem.</i> (2001).	
	FN	Walker <i>et al.</i> , "Conditions for the Chemical and Physical Inactivation of the K. Fu. Strain of the Agent of Creutzfeldt-Jacob Disease", <i>Am. J. Public Health</i> 73: 661-665 (1983).	
	FO	Walmsley, AR, "Membrane topology influences N-glycosylation of the prion protein," <i>EMBO J</i> , 20(4):703-712 (2001).	
	FP	Wille, <i>et al.</i> , "Prion protein amyloid: separation of scrapie infectivity from PrP polymers," <i>Ciba Found Symp</i> , 199:181-99 (1996).	
	FQ	Wille, <i>et al.</i> , "Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein," 130(2-3):323-38 (2000).	
	FR	Wille, <i>et al.</i> , "Separation of scrapie prion infectivity from PrP amyloid polymers," <i>J Mol Biol</i> , 259(4):608:21 (1996).	
	FS	Winkhofer, KF, "Cationic lipopolyamines induce degradation of PrPSc in scrapie mouse neuroblastoma cells," <i>Biol Chem</i> , 381(5-6):463-9 (2000).	
	FT	Witvrouw <i>et al.</i> , "Sulfated Polysaccharides Extracted from Sea Algae as Potential Antiviral Drugs," <i>Gen. Pharmacol.</i> 29(4):497-511 (1997).	
	FU	Wong, <i>et al.</i> , "Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein," <i>EMBO J</i> , 20(3):377-86 (2001).	
	FV	World Health Organization, "WHO infection control guidelines for transmissible spongiform encephalopathies," http://www.who.int/emc; who/cds/csr/aph/2000.3, 03/23-26/(1999).	
	FW	Zaretzky <i>et al.</i> , "Sulfated Polyanions Block <i>Chlamydia Trachomatis</i> Infection of Cervix-Derived Human Epithelia," <i>Infect. Immun.</i> 63(9):3520-3526 (1995).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.